Hormonal therapy of prostate cancer

Seminars in Urologic Oncology

Volumn 20, Issue 3 SUPPL. 1, 2002, Pages 4-9

  Debruyne, Frans ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; DIETHYLSTILBESTROL; FOLLITROPIN; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; TESTOSTERONE;

ARTICLE; CANCER HORMONE THERAPY; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CASTRATION; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; HUMAN; MALE; ORCHIECTOMY; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE;

EID: 0036671490     PISSN: 10810943     EISSN: None     Source Type: Journal    
DOI: 10.1053/suro.2002.35051     Document Type: Article

References (30)

1. U.S. cancer incidence, mortality and survival: 1973-1996
2. Cancer statistics 2000
3. International trends in prostate-cancer mortality in the "PSA era."
4. Determination of county-level prostate carcinoma incidence and detection rates with Medicare claims data
5. Studies on prostatic cancer: Effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate
6. Androgenic activity of dehydroepiandrosterone and androstenedione in the rat ventral prostate
7. The Veterans' Administration Cooperative Urological Research Group studies of carcinoma of the prostate: A review
8. Hormone therapy for prostate cancer: Results of the Veterans Administration Cooperative Urological Research Group studies of cancer of the prostate
9. Histologic grade, clinical stage, and patient age in prostate cancer
10. Cardiovascular side effects of diethylstilbestrol, cyproterone acetate, medroxyprogesterone acetate and estramustine phosphate used for the treatment of advanced prostatic cancer: Results from European Organization for Research on Treatment of Cancer trials 30761 and 30762
11. Diethylstilbestrol is an active agent in prostate cancer patients after failure to complete andrigen blockade
12. Leuprolide versus diethylstilbestrol for metastatic prostate cancer
13. Physiologic basis of endocrine therapy for prostatic cancer
14. Stronger suppression of serum testosterone and FSH levels by a synthetic estrogen than by castration or an LH-RH agonist
15. Clinical effects of gonadotropin-releasing hormone analogue in metastatic carcinoma of prostate
16. Differential response of prostate specific antigen to testosterone surge after luteinizing hormone-releasing hormone analogue in prostate cancer and benign prostatic hyperplasia
17. Role of insulin-like growth factors and their binding proteins in growth control and carcinogenesis
18. Growth regulation of prostatic stromal cells by prostate-specific antigen
19. Is disease flare a problem?
20. Follicle-stimulating hormone (FSH) escape during chronic gonadotropin-releasing hormone (GnRH) agonist and testosterone treatment
21. Sudden death due to disease flare with luteinizing hormone-releasing hormone agonist therapy for carcinoma of the prostate
22. Prevention of the transient adverse effects of a gonadotropin-releasing hormone analogue (buserelin) in metastatic prostatic carcinoma by administration of an antiandrogen (nilutamide)
23. Leuprolide acetate (30-mg depot every four months) in the treatment of advanced prostate cancer
24. Simultaneous administration of pure antiandrogens, a combination necessary for the use of luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer
25. Controlled trial of leuprolide with and without flutamide in prostatic carcinoma
26. Treatment of newly diagnosed state D2 prostate cancer with leuprolide and flutamide or leuprolide alone, phase III, intergroup study 0036
27. Maximum androgen blockade in advanced prostate cancer: An overview of the randomised trials
28. Luteinizing hormone-releasing hormone antagonists in prostate cancer
29. Technology evaluation: Abarelix, Praecis Pharmaceuticals
30. The gonadotropinreleasing hormone antagonist abarelix depot versus luteinizing hormone releasing hormone agonists leuprolide or goserelin: Initial results of endocrinological and biochemical efficacies in patients with prostate cancer